{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:58:35Z","timestamp":1781085515615,"version":"3.54.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hematologic malignancies impose substantial economic burdens, but the quantitative association between financial toxicity and overall survival remains poorly defined across diverse clinical settings and disease lineages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adhering to PRISMA and MOOSE guidelines, we searched electronic databases through January 2026 for studies reporting multivariable-adjusted hazard ratios (aHRs) for the association between financial toxicity and mortality in adults diagnosed with hematologic malignancies. A random-effects model with Hartung\u2013Knapp adjustment was used for data synthesis. Small-study effects were addressed via the Duval and Tweedie trim-and-fill method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven cohorts involving 280\u00a0826 individuals were included. Meta-analysis identified a significant association between financial toxicity and inferior survival (pooled aHR: 1.57; 95% CI, 1.29-1.91; P\u2009&amp;lt;\u2009.001). High heterogeneity (I2\u2009=\u200985.1%) and a wide 95% prediction interval (0.89-2.77) indicated substantial variability across settings. Subgroup analysis revealed that mortality risk was primarily linked to structural barriers, specifically lack of insurance (aHR: 1.66; 95% CI, 1.39-1.99), whereas this association was weaker in specialized transplant settings with integrated psychosocial support. Findings remained statistically significant after trim-and-fill adjustment for potential publication bias (adjusted aHR: 1.33; 95% CI, 1.05-1.69; P\u2009=\u2009.023).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Financial toxicity is a significant factor independently associated with mortality in hematologic malignancies. The strength of this association varies depending upon the care environment, with structural access barriers representing the highest risk. Integrating proactive financial navigation into standard clinical pathways is essential to alleviate socioeconomic disparities and may help improve survival outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag178","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:17:59Z","timestamp":1777893479000},"source":"Crossref","is-referenced-by-count":0,"title":["The association between financial toxicity and mortality in hematologic malignancies: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3678-2179","authenticated-orcid":false,"given":"Fang","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Hematology, Chinese People's Liberation Army, The General Hospital of Western Theater Command, Chengdu , Sichuan 610083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-xia","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People's Liberation Army, The General Hospital of Western Theater Command, Chengdu , Sichuan 610083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People's Liberation Army, The General Hospital of Western Theater Command, Chengdu , Sichuan 610083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-qiong","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, Chinese People's Liberation Army, The General Hospital of Western Theater Command, Chengdu , Sichuan 610083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2256-9166","authenticated-orcid":false,"given":"Dan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People's Liberation Army, The General Hospital of Western Theater Command, Chengdu , Sichuan 610083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026061005111977500_oyag178-B1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026061005111977500_oyag178-B2","doi-asserted-by":"publisher","first-page":"8896","DOI":"10.3390\/jcm14248896","article-title":"The precision revolution in hematologic malignancies: a decade of transformative immunotherapies and targeted agents","volume":"14","author":"Mansour","year":"2025","journal-title":"J Clin Med"},{"key":"2026061005111977500_oyag178-B3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11899-023-00707-6","article-title":"Financial toxicity in patients with hematologic malignancies: a review and need for interventions","volume":"18","author":"Sears-Smith","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"2026061005111977500_oyag178-B4","doi-asserted-by":"publisher","first-page":"djv370","DOI":"10.1093\/jnci\/djv370","article-title":"Financial toxicity of cancer care: it\u2019s time to intervene","volume":"108","author":"Zafar","year":"2016","journal-title":"Note. J Natl Cancer Inst"},{"key":"2026061005111977500_oyag178-B5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3322\/caac.21443","article-title":"The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2026061005111977500_oyag178-B6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/cncr.33267","article-title":"The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States","volume":"127","author":"Seymour","year":"2021","journal-title":"Cancer"},{"key":"2026061005111977500_oyag178-B7","doi-asserted-by":"publisher","first-page":"E619","DOI":"10.1016\/j.clml.2021.02.013","article-title":"Risk factors for cost-related delays to medical care among lymphoma patients: a 22-year analysis of a nationally representative sample","volume":"21","author":"Jella","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026061005111977500_oyag178-B8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026061005111977500_oyag178-B9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","article-title":"Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications","volume":"30","author":"Witte","year":"2019","journal-title":"Ann Oncol"},{"key":"2026061005111977500_oyag178-B10","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.1007\/s00520-022-07044-z","article-title":"Financial toxicity of cancer care in low- and middle-income countries: a systematic review and meta-analysis","volume":"30","author":"Donkor","year":"2022","journal-title":"Support Care Cancer"},{"key":"2026061005111977500_oyag178-B11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026061005111977500_oyag178-B12","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"2026061005111977500_oyag178-B13","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3109\/10428194.2015.1011156","article-title":"Socioeconomic status is independently associated with overall survival in patients with multiple myeloma","volume":"56","author":"Fiala","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2026061005111977500_oyag178-B14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1159\/000514671","article-title":"Survival disparities in multiple myeloma by health insurance status among US non-elderly adults: a SEER-based comparative analysis","volume":"144","author":"Huang","year":"2021","journal-title":"Acta Haematol"},{"key":"2026061005111977500_oyag178-B15","author":"Wells"},{"key":"2026061005111977500_oyag178-B16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/OP.2025.21.10_suppl.310","article-title":"Financial toxicity after bone marrow transplant (BMT): a longitudinal, prospective study of quality of life and outcomes","volume":"21","author":"Hussaini","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"2026061005111977500_oyag178-B17","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1182\/blood-2023-179629","article-title":"Medical insurance coverage and clinical outcomes for patients with hematological malignancies in a rural state","volume":"142","author":"Nnawuba","year":"2023","journal-title":"Blood"},{"key":"2026061005111977500_oyag178-B18","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1080\/10428194.2022.2102623","article-title":"Insurance-based disparities impact survival outcomes in Waldenstr\u00f6m macroglobulinemia within the United States","volume":"63","author":"Chohan","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2026061005111977500_oyag178-B19","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3390\/cancers13040590","article-title":"Socioeconomic factors and survival of multiple myeloma patients","volume":"13","author":"Chamoun","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026061005111977500_oyag178-B20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/1055-9965.Epi-17-1040","article-title":"Financial hardship after hematopoietic cell transplantation: lack of impact on survival","volume":"27","author":"Khera","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026061005111977500_oyag178-B21","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood-2018-03-839035","article-title":"Disparities in survival by insurance status in follicular lymphoma","volume":"132","author":"Goldstein","year":"2018","journal-title":"Blood"},{"key":"2026061005111977500_oyag178-B22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood.V130.Suppl_1.915.915","article-title":"Survival outcome and insurance status among Hodgkin\u2019s lymphoma (HL) patients: data from SEER 2007-2014","volume":"130","author":"Wang","year":"2017","journal-title":"Blood"},{"key":"2026061005111977500_oyag178-B23","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cncr.30639","article-title":"Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: a population-based study","volume":"123","author":"Perry","year":"2017","journal-title":"Cancer"},{"key":"2026061005111977500_oyag178-B24","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","article-title":"Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era","volume":"123","author":"Tao","year":"2014","journal-title":"Blood"},{"key":"2026061005111977500_oyag178-B25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4103\/ijph.ijph_1168_23","article-title":"Socioeconomic factors influencing treatment and outcomes in acute myeloid leukemia","volume":"69","author":"Nethala","year":"2025","journal-title":"Indian J Public Health"},{"key":"2026061005111977500_oyag178-B26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13643-025-02752-z","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance","volume":"14","author":"Tierney","year":"2025","journal-title":"Syst Rev"},{"key":"2026061005111977500_oyag178-B27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s44313-025-00069-3","article-title":"Real-world treatment patterns, outcomes, and economic costs by lines of therapy in patients with newly diagnosed multiple myeloma: a nationwide population-based cohort study in South Korea","volume":"60","author":"Park","year":"2025","journal-title":"Blood Res"},{"key":"2026061005111977500_oyag178-B28","doi-asserted-by":"publisher","first-page":"Op2500967","DOI":"10.1200\/op-25-00967","article-title":"Interplay between psychological burden, economic stress, and quality of life in chronic myeloid leukemia care: an integrated analysis","volume":"10","author":"Cheng","year":"2026","journal-title":"JCO Oncol Pract"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag178\/68246655\/oyag178.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag178\/68246655\/oyag178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag178\/68246655\/oyag178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:11:29Z","timestamp":1781082689000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag178\/8672524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag178","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,7]]},"article-number":"oyag178"}}